CellVec at ISCT 2021

Dr. Paula Lam, Head of Research & Development at CellVec, shared about the efficiency of our GMP-compliant LV manufacturing process at ISCT2021. With high yield, high purity vector stocks, GMP vector products that are highly potent on primary T cells and stable transduction efficiencies, every batch of GMP lentiviral vectors manufactured with our scalable in-house process should provide sufficient quantities for up to 200 patients in a Car-T cell manufacturing setting.